International Multi-Site Initiative to Develop an MRI-Inclusive Nomogram for Side-Specific Prediction of Extraprostatic Extension of Prostate Cancer.

clinical staging extraprostatic tumor extension magnetic resonance imaging nomogram prostate cancer

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
27 May 2021
Historique:
received: 31 03 2021
revised: 29 04 2021
accepted: 21 05 2021
entrez: 2 6 2021
pubmed: 3 6 2021
medline: 3 6 2021
Statut: epublish

Résumé

To develop an international, multi-site nomogram for side-specific prediction of extraprostatic extension (EPE) of prostate cancer based on clinical, biopsy, and magnetic resonance imaging- (MRI) derived data. Ten institutions from the USA and Europe contributed clinical and side-specific biopsy and MRI variables of consecutive patients who underwent prostatectomy. A logistic regression model was used to develop a nomogram for predicting side-specific EPE on prostatectomy specimens. The performance of the statistical model was evaluated by bootstrap resampling and cross validation and compared with the performance of benchmark models that do not incorporate MRI findings. Data from 840 patients were analyzed; pathologic EPE was found in 320/840 (31.8%). The nomogram model included patient age, prostate-specific antigen density, side-specific biopsy data (i.e., Gleason grade group, percent positive cores, tumor extent), and side-specific MRI features (i.e., presence of a PI-RADSv2 4 or 5 lesion, level of suspicion for EPE, length of capsular contact). The area under the receiver operating characteristic curve of the new, MRI-inclusive model (0.828, 95% confidence limits: 0.805, 0.852) was significantly higher than that of any of the benchmark models ( In an international, multi-site study, we developed an MRI-inclusive nomogram for the side-specific prediction of EPE of prostate cancer that demonstrated significantly greater accuracy than clinical benchmark models.

Sections du résumé

BACKGROUND BACKGROUND
To develop an international, multi-site nomogram for side-specific prediction of extraprostatic extension (EPE) of prostate cancer based on clinical, biopsy, and magnetic resonance imaging- (MRI) derived data.
METHODS METHODS
Ten institutions from the USA and Europe contributed clinical and side-specific biopsy and MRI variables of consecutive patients who underwent prostatectomy. A logistic regression model was used to develop a nomogram for predicting side-specific EPE on prostatectomy specimens. The performance of the statistical model was evaluated by bootstrap resampling and cross validation and compared with the performance of benchmark models that do not incorporate MRI findings.
RESULTS RESULTS
Data from 840 patients were analyzed; pathologic EPE was found in 320/840 (31.8%). The nomogram model included patient age, prostate-specific antigen density, side-specific biopsy data (i.e., Gleason grade group, percent positive cores, tumor extent), and side-specific MRI features (i.e., presence of a PI-RADSv2 4 or 5 lesion, level of suspicion for EPE, length of capsular contact). The area under the receiver operating characteristic curve of the new, MRI-inclusive model (0.828, 95% confidence limits: 0.805, 0.852) was significantly higher than that of any of the benchmark models (
CONCLUSIONS CONCLUSIONS
In an international, multi-site study, we developed an MRI-inclusive nomogram for the side-specific prediction of EPE of prostate cancer that demonstrated significantly greater accuracy than clinical benchmark models.

Identifiants

pubmed: 34071842
pii: cancers13112627
doi: 10.3390/cancers13112627
pmc: PMC8198352
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Organisme : Peter Michael Foundation
ID : N/A

Références

Urology. 2010 Dec;76(6):1298-301
pubmed: 21030068
Diagn Progn Res. 2019 Oct 4;3:18
pubmed: 31592444
Med Decis Making. 2006 Nov-Dec;26(6):565-74
pubmed: 17099194
J Magn Reson Imaging. 2019 Nov;50(5):1604-1613
pubmed: 30957321
PLoS One. 2019 Jan 7;14(1):e0210194
pubmed: 30615661
Urol Oncol. 2019 Mar;37(3):181.e1-181.e6
pubmed: 30558983
J Urol. 2020 Jun;203(6):1085-1093
pubmed: 31609177
AJR Am J Roentgenol. 2015 Jul;205(1):W73-8
pubmed: 26102421
J Urol. 2018 Nov;200(5):1041-1047
pubmed: 29852182
Eur Urol. 2016 Jan;69(1):16-40
pubmed: 26427566
Radiology. 2016 Sep;280(3):793-804
pubmed: 27035179
Acta Radiol. 2020 Nov;61(11):1570-1579
pubmed: 32108505
J Urol. 2006 Mar;175(3 Pt 1):939-44; discussion 944
pubmed: 16469587
Radiology. 2012 Mar;262(3):874-83
pubmed: 22274837
Oncotarget. 2017 Mar 28;8(13):22095-22103
pubmed: 27564265
J Endourol. 2007 Nov;21(11):1345-51
pubmed: 18042028
BJU Int. 2013 Jan;111(1):22-9
pubmed: 22834909
World J Urol. 2017 Sep;35(9):1409-1415
pubmed: 27995303
Med Pharm Rep. 2020 Apr;93(2):150-161
pubmed: 32478321
Can Urol Assoc J. 2017 May;11(5):E174-E178
pubmed: 28503230
Eur Radiol. 2010 Apr;20(4):995-1002
pubmed: 19921205
Urol Oncol. 2009 Mar-Apr;27(2):174-9
pubmed: 18640062
Front Oncol. 2020 Jun 16;10:940
pubmed: 32612953
Eur Radiol. 2012 Apr;22(4):746-57
pubmed: 22322308
Urology. 2018 Mar;113:119-128
pubmed: 29217354
Eur Urol. 2016 Aug;70(2):233-45
pubmed: 26215604
Eur Urol Oncol. 2018 Sep;1(4):338-345
pubmed: 31100256
Int Urol Nephrol. 2019 Sep;51(9):1545-1552
pubmed: 31190297
J Urol. 2020 Jul;204(1):24-32
pubmed: 31967522
Urology. 2015 Aug;86(2):332-7
pubmed: 26194289
BJU Int. 2017 Nov;120(5B):E45-E51
pubmed: 27987524
Eur Radiol. 2021 Apr 1;:
pubmed: 33792737
Eur Urol. 2015 Sep;68(3):487-96
pubmed: 25813692
J Urol. 2020 Jul;204(1):82-90
pubmed: 31977261
Acad Radiol. 2019 Oct;26(10):1338-1344
pubmed: 30655050
BJU Int. 2018 Dec;122(6):1025-1033
pubmed: 29676063
Eur Urol Oncol. 2019 Nov;2(6):605-616
pubmed: 31204311
Radiology. 2006 Jan;238(1):184-91
pubmed: 16304091
Eur Urol Focus. 2020 Nov 15;6(6):1205-1212
pubmed: 30477971
J Urol. 2010 Mar;183(3):952-7
pubmed: 20083260
AJR Am J Roentgenol. 2017 Aug;209(2):W76-W84
pubmed: 28570124
Eur Urol. 2017 May;71(5):701-704
pubmed: 27576750

Auteurs

Andreas G Wibmer (AG)

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Michael W Kattan (MW)

Department of Quantitative Health Sciences in the Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Francesco Alessandrino (F)

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Alexander D J Baur (ADJ)

Charité University Hospital, 10117 Berlin, Germany.

Lars Boesen (L)

Herlev Gentofte University Hospital, 2730 Herlev, Denmark.

Felipe Boschini Franco (FB)

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

David Bonekamp (D)

DKFZ German Cancer Research Center, 69120 Heidelberg, Germany.

Riccardo Campa (R)

Department of Radiological Sciences, Oncology & Pathology, Sapienza University of Rome, 00185 Rome, Italy.

Hannes Cash (H)

Charité University Hospital, 10117 Berlin, Germany.
Department of Urology, University Magdeburg, 39120 Magdeburg, Germany.

Violeta Catalá (V)

Department of Radiology, Fundació Puigvert, 08025 Barcelona, Spain.
Department of Uro-Radiology, Creu Blanca, 08034 Barcelona, Spain.

Sebastien Crouzet (S)

Hospices Civils de Lyon, Hôpital Edouard Herriot, 69003 Lyon, France.

Sounil Dinnoo (S)

Genitourinary and Women's Imaging Departments, Lille University Hospital, 59037 Lille, France.

James Eastham (J)

Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Fiona M Fennessy (FM)

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Kamyar Ghabili (K)

Department of Urology, Yale School of Medicine, New Haven, CT 06510, USA.

Markus Hohenfellner (M)

Department of Urology, University Hospital of Heidelberg, 69120 Heidelberg, Germany.

Angelique W Levi (AW)

Department of Pathology, Yale School of Medicine, New Haven, CT 06510, USA.

Xinge Ji (X)

Department of Quantitative Health Sciences in the Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Vibeke Løgager (V)

Herlev Gentofte University Hospital, 2730 Herlev, Denmark.

Daniel J Margolis (DJ)

Weill Cornell Medicine, Weill Cornell Imaging, New York-Presbyterian Hospital, New York, NY 10021, USA.

Paul C Moldovan (PC)

Hospices Civils de Lyon, Hôpital Edouard Herriot, 69003 Lyon, France.

Valeria Panebianco (V)

Department of Radiological Sciences, Oncology & Pathology, Sapienza University of Rome, 00185 Rome, Italy.

Tobias Penzkofer (T)

Charité University Hospital, 10117 Berlin, Germany.
Berlin Institute of Health (BIH), 10178 Berlin, Germany.

Philippe Puech (P)

Genitourinary and Women's Imaging Departments, Lille University Hospital, 59037 Lille, France.

Jan Philipp Radtke (JP)

DKFZ German Cancer Research Center, 69120 Heidelberg, Germany.
Department of Urology, University Hospital of Heidelberg, 69120 Heidelberg, Germany.

Olivier Rouvière (O)

Hospices Civils de Lyon, Hôpital Edouard Herriot, 69003 Lyon, France.
Faculté de Médecine Lyon Est, Université de Lyon, 69003 Lyon, France.

Heinz-Peter Schlemmer (HP)

DKFZ German Cancer Research Center, 69120 Heidelberg, Germany.

Preston C Sprenkle (PC)

Department of Urology, Yale School of Medicine, New Haven, CT 06510, USA.

Clare M Tempany (CM)

Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

Joan C Vilanova (JC)

Clínica Girona, Institute Catalan of Health-IDI, University of Girona, 17004 Girona, Spain.

Jeffrey Weinreb (J)

Department of Radiology, Yale School of Medicine, New Haven, CT 06510, USA.

Hedvig Hricak (H)

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Amita Shukla-Dave (A)

Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

Classifications MeSH